Johnson & Johnson (NYSE:JNJ) is Robinson Smith Wealth Advisors LLC’s 3rd Largest Position

Robinson Smith Wealth Advisors LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 9.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,717 shares of the company’s stock after selling 3,709 shares during the period. Johnson & Johnson comprises 4.6% of Robinson Smith Wealth Advisors LLC’s investment portfolio, making the stock its 3rd biggest position. Robinson Smith Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $5,455,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of JNJ. Signature Wealth Management Group increased its position in Johnson & Johnson by 4.9% during the fourth quarter. Signature Wealth Management Group now owns 27,864 shares of the company’s stock worth $4,030,000 after buying an additional 1,295 shares in the last quarter. SlateStone Wealth LLC increased its position in Johnson & Johnson by 2.4% during the fourth quarter. SlateStone Wealth LLC now owns 69,864 shares of the company’s stock worth $10,104,000 after buying an additional 1,637 shares in the last quarter. First National Advisers LLC grew its position in shares of Johnson & Johnson by 2.8% in the fourth quarter. First National Advisers LLC now owns 19,064 shares of the company’s stock valued at $2,757,000 after purchasing an additional 527 shares during the period. GWN Securities Inc. acquired a new position in Johnson & Johnson in the fourth quarter valued at $2,928,000. Finally, Van Hulzen Asset Management LLC increased its stake in Johnson & Johnson by 1.2% in the fourth quarter. Van Hulzen Asset Management LLC now owns 153,400 shares of the company’s stock valued at $22,182,000 after purchasing an additional 1,807 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

JNJ opened at $162.94 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The stock has a fifty day moving average of $154.98 and a 200-day moving average of $156.32. The firm has a market capitalization of $392.29 billion, a P/E ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same period last year, the business posted $2.29 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Analysts Set New Price Targets

JNJ has been the subject of several analyst reports. Citigroup dropped their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Raymond James dropped their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Wells Fargo & Company dropped their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Morgan Stanley dropped their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.